Literature DB >> 1708183

Recognition of a hepatitis B virus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit B of Escherichia coli heat labile enterotoxin in attenuated salmonellae.

F Schödel1, G Enders, M C Jung, H Will.   

Abstract

Two overlapping T-cell sites of the nucleocapsid antigen (HBc) of Hepatitis B Virus (HBV) (amino acids (aa) 120-140) and a B-cell epitope of the pre-S(2) region of the HBV surface antigen (aa 133-140) were expressed as a fusion protein with the subunit B of Escherichia coli heat labile enterotoxin (LT-B) in attenuated salmonellae (aroA Salmonella dublin SL1438). When Balb/c (haplotype H-2d) mice were fed salmonellae expressing LT-B or the LT-B/HBV fusion protein they developed serum IgG anti-LT-B antibodies and splenic cells reactive to LT-B. C57BL/10 (H-2b), in contrast, showed anti-LT-B antibody titres, but no splenic cell priming to LT-B. Neither in Balb/c nor in C57BL/10 mice could an antibody response to the fused HBV antibody binding site be demonstrated. In C57BL/10, however, an HBc T-cell epitope fused to LT-B primed a splenic cell response to an analogous synthetic peptide (HBc aa 121-145) in four out of five mice after three oral immunizations. This is the first description of the priming of a cellular immune response to a defined heterologous epitope expressed in attenuated salmonellae and delivered by the oral route.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1708183     DOI: 10.1016/0264-410x(90)90010-j

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

2.  Development of an immunoassay using recombinant maltose-binding protein-STa fusions for quantitating antibody responses against STa, the heat-stable enterotoxin of Escherichia coli.

Authors:  R Aitken; T R Hirst
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

Review 3.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

4.  The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.

Authors:  J Benyacoub; S Hopkins; A Potts; S Kelly; J P Kraehenbuhl; R Curtiss; P De Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

5.  A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

Authors:  S Hopkins; J P Kraehenbuhl; F Schödel; A Potts; D Peterson; P de Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Authors:  Dominique Fraillery; David Baud; Susana Yuk-Ying Pang; John Schiller; Martine Bobst; Nathalie Zosso; Françoise Ponci; Denise Nardelli-Haefliger
Journal:  Clin Vaccine Immunol       Date:  2007-08-08

7.  Oral immunization of mice and swine with an attenuated Salmonella choleraesuis [delta cya-12 delta(crp-cdt)19] mutant containing a recombinant plasmid.

Authors:  T J Stabel; J E Mayfield; D C Morfitt; M J Wannemuehler
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

8.  Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide.

Authors:  E A Merritt; S Sarfaty; F van den Akker; C L'Hoir; J A Martial; W G Hol
Journal:  Protein Sci       Date:  1994-02       Impact factor: 6.725

9.  Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.

Authors:  David Baud; Françoise Ponci; Martine Bobst; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.